SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES
SILENCE THERAPEUTICS AND MALLINCKRODT ANNOUNCE COLLABORATION TO DEVELOP AND COMMERCIALIZE RNAi THERAPEUTICS FOR COMPLEMENT-MEDIATED DISEASES — Collaboration advances Silence’s proprietary platform in the growing field…